rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SER
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Serina Therapeutics Streamlines Capital Structure After Preferred Elimination

      Tipranks Press Release.

      Oct 10The Globe and MailSER
      Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
      Sep 23Yahoo FinanceSER
      Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event 'A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress'

      Featuring Serina Therapeutics’ CEO - Thursday, September 24, 202610M people in the world currently living with Parkinson’s diseasewith no major cl...

      Sep 23Business InsiderSER
      Serina Therapeutics at H.C. Wainwright conference: Parkinson’s push advances
      Sep 11Investing.comSER
      Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend o

      Sep 10Yahoo FinanceSER
      Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

      - Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures – - Serina expects to report topline data from the single-

      Sep 9Yahoo FinanceSER
      Serina Therapeutics Establishes Flexible Equity Financing Agreement

      Detailed price information for Serina Therapeutics Inc (SER-A) from The Globe and Mail including charting and trades.

      Aug 28The Globe and MailSER
      Analysts Are Bullish on These Healthcare Stocks: Tvardi Therapeutics (TVRD), GE Healthcare Technologies Inc (GEHC)

      Detailed price information for GE Healthcare Technologies (GEHC-Q) from The Globe and Mail including charting and trades.

      Aug 21The Globe and MailSER

      This is the newest page. Registered accounts read further back.